Anania Caterina, Matys Viviana, Marra Simona, De Canditiis Daniela, Olivero Francesca, Carraro Carlo, Giugliano Anna, Zicari Anna Maria, Piccioni Maria Grazia
Department of Maternal, Infantile and Urological Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Institute for the Application of Calculus (IAC)-CNR, 00185 Rome, Italy.
Nutrients. 2025 Feb 13;17(4):673. doi: 10.3390/nu17040673.
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by the appearance of recurrent eczematous lesions and intense itching. The World Allergy Organization (WAO) suggested the administration of probiotics in pregnant women at high risk of allergies in their children.
Our study aims to evaluate the role of administering the strain PRL2010 during pregnancy and breastfeeding in preventing and/or reducing the severity of AD manifestations in children.
It is a monocentric, randomized, double-blind, placebo-controlled trial with probiotic/placebo administration since the 36th week of gestation to mothers with atopy or a family history of atopy; the effects were evaluated over the first 12 months of the children's lives.
No severe adverse effects due to probiotic intake were reported in our cohort. Although proportionally fewer children with AD were in the probiotic group, the statistical analysis showed no significant differences between the probiotic and placebo groups. However, infants who developed the most severe forms of AD in the probiotic group showed a better clinical course during follow-up compared to those in the placebo group.
In conclusion, administering the probiotic strain PRL2010 during pregnancy and breastfeeding is safe and potentially beneficial; further large-scale studies may confirm its usefulness in improving the clinical manifestation of AD in children with a family history of atopy.
特应性皮炎（AD）是一种慢性炎症性皮肤病，其特征为反复出现湿疹样皮损和剧烈瘙痒。世界过敏组织（WAO）建议对子女有高过敏风险的孕妇给予益生菌。
我们的研究旨在评估孕期及哺乳期给予PRL2010菌株在预防和/或减轻儿童AD表现严重程度方面的作用。
这是一项单中心、随机、双盲、安慰剂对照试验，自妊娠第36周起对有特应性或特应性家族史的母亲给予益生菌/安慰剂；在儿童生命的前12个月评估效果。
我们的队列中未报告因摄入益生菌导致的严重不良反应。虽然益生菌组患AD的儿童比例相对较少，但统计分析显示益生菌组和安慰剂组之间无显著差异。然而，与安慰剂组相比，益生菌组中患最严重形式AD的婴儿在随访期间临床病程更好。
总之，孕期及哺乳期给予益生菌PRL2010菌株是安全且可能有益的；进一步的大规模研究可能证实其对改善有特应性家族史儿童AD临床表现的有效性。
